AGENCE NATIONALE DU
MEDICAMENT VETERINAIRE

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

RILEXINE DC 375 MG
INTRAMAMMARY SUSPENSION FOR DRY COWS

DATE : 16/03/2022

French agency for food, environnemental and occupational health safety– French Agency for Veterinary Medicinal Products
14 rue Claude Bourgelat – Parc d'activités de la grande Marche – Javené – CS 70611 – 35306 FOUGERES - Téléphone : + 33 (0)2 99 94 78 78 - Télécopie : + 33 (0)2 99 94 78 60 - www.anses.fr

MODULE 1

PRODUCT SUMMARY

EU Procedure number	FR/V/0438/001/DC
Name, strength and pharmaceutical form	RILEXINE DC 375 mg INTRAMAMMARY SUSPENSION FOR DRY COWS
Applicant	VIRBAC 1ERE AVENUE 2065 M L I D 06516 CARROS CEDEX FRANCE
Active substance(s)	Cefalexin (as benzathine)
ATC Vetcode	QJ51DB01
Target species	Cattle (dry cows)
Indication for use	For the treatment of subclinical mastitis at dry-off and prevention of new intramammary infections occurring during the dry period, caused by Staphylococcus aureus, Streptococcus dysgalactiae and Streptococcus uberis, susceptible to cefalexin.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the website https://www.anses.fr/en/thematique/veterinary-medicine-anmv

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Hybrid application in accordance with Article 13(3) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	09/02/2022
Concerned Member States for original procedure	AT, BE, BG, CZ, DE, DK, EE, ES, FI, HR, HU, IE, IT, LT, LV, NL, PL, PT, RO, SI, SK, UK (NI)

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the observed possible reactions are indicated in the SPC.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Composition

The product contains 375 mg of cefalexin, as benzathine derivative with aluminium stearate, white soft paraffin and light liquid paraffin as excipients.
The packaging of the finished product is as described on the SPC. The particulars of the containers and controls performed are provided and conform to the regulation.
The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.
Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is cefalexin, as benzathine derivative, an established active substance. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

E. Control on intermediate products

Not applicable.

F. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.
Satisfactory validation data for the analytical methods have been provided.
Batch analytical data from the proposed production sites have been provided demonstrating compliance with the specification.

G. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

H. Genetically Modified Organisms

Not applicable.

J. Other Information

Not applicable.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

III.A Safety Testing

Pharmacological Studies

See part IV.

Toxicological Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product are identical to the reference product.

User Safety

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of user safety assessment are not required.

The user safety aspects of this product are identical to the reference product.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the initial predicted environmental concentration in soil is less than 100 µg/kg.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to the environment.

III.B Residues documentation

Residue Studies

No residue depletion studies were conducted because the type of application, an auto-hydrid of an intramammary product with an alleged identical composition in regards of that of the reference product.

MRLs

The active substance, cefalexin, is included in table 1 of the annex of the Commission Regulation (EU) No. 37/2010, as follows,

Marker residue	Animal Species	MRL	Target Tissues	Other Provisions	Therapeutic Classification	Regulation
Cefalexin	Bovine	200 µg/kg 200 µg/kg 200 µg/kg 1 000 µg/kg 100 µg/kg	Muscle Fat Liver Kidneys Milk	No entry	Anti-infectious agents/ Antibiotics	37/2010 of 22.12.2009

The composition of the product RILEXINE DC 375 MG INTRAMAMMARY SUSPENSION FOR DRY COWS is acceptable according to the European regulation (EC) No 470/2009.

Withdrawal Periods

As bioequivalence based on biowaiver is confirmed, the withdrawal periods of the reference product could be applied for the candidate product, as follows :

Meat and offal: 4 days
Milk:
12 hours after calving when dry period is more than 42 days
42.5 days after treatment when dry period is 42 days or less.

IV. CLINICAL ASSESSMENT (EFFICACY)

IV.A Pre-Clinical Studies

Pharmacology

This application for marketing authorization is made according to the provisions of Article 13.3 of Directive 2001/82/EC as amended by Directive 2004/28/EC. The Reference Product RILEXINE HL is marketed by Virbac too, and has been authorized in France since 27/09/1989.

Pharmaceutical form
The test and the reference products have the same pharmaceutical form: intramammary suspension.

Active substance qualitative and quantitative composition
The test and reference products have the same qualitative and quantitative composition in active substance :
375 mg of cefalexin as benzathine per 8 g intramammary syringe

Bioequivalence studies
No study was provided.
The test and reference products are considered bioequivalent based on Guideline on the conduct of bioequivalence studies for veterinary medicinal product » (EMA/CVMP/016/2000-Rev.3) Appendix I section 7.1.

Tolerance in the Target Species of Animals

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of tolerance in the target species of animals are not required.

The tolerance aspects of this product are identical to the reference product.

Warnings and precautions as listed on the product literature are adequate to ensure safety of target species of the product.

Resistance

The applicant has documented the current status of resistance to cefalexin in bacterial target pathogens. Adequate warnings and precautions appear on the product literature.

IV.B Clinical Studies

This is a Hybrid application in accordance with Article 13(3) of Directive 2001/82/EC, as amended by Directive 2004/28/EC. As the bioequivalence with the reference product can be assumed, the applicant is not required to submit clinical data. Therefore, the efficacy claims for this product are equivalent to those of the reference product.

V. OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk / benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website (https://www.hma.eu/veterinarymedicines.html).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

None